

### Organizing committee

**Dr. Vicente Alonso**  
Hospital Universitario Miguel Servet, Zaragoza

**Dr. Jorge Aparicio**  
Hospital Universitari i Politècnic La Fe, Valencia

**Dr. Juan Ramón Ayuso**  
Hospital Clínic, Barcelona

**Dr. Jaume Capdevila**  
Hospital Universitari Vall d'Hebron, Barcelona

**Dr. Laura Cerezo**  
Hospital Universitario de La Princesa, Madrid

**Dr. Jaime Feliu**  
Hospital Universitario La Paz, Madrid

**Dr. Carlos Fernández Martos**  
Fundación Instituto Valenciano de Oncología, Valencia

**Dra. Rocío García Carbonero**  
Hospital Universitario 12 de Octubre, Madrid

**Dr. Xabier García de Albéniz**  
RTI-Health Solutions, Barcelona

**Dr. Fernando López Campos**  
Hospital Universitario Ramón y Cajal, Madrid

**Dr. Marta Martín Richard**  
Hospital de la Santa Creu i Sant Pau, Barcelona

**Dr. Joan Maurel**  
Hospital Clínic, Barcelona

**Dr. Manel Pera**  
Hospital del Mar, Barcelona

**Dr. Anna Reig**  
Hospital del Mar, Barcelona

**Dr. Javier Suarez**  
Complejo Universitario de Navarra, Pamplona

### Scientific committee

**Dr. Salah-Eddin Al-Batran**  
Institute of Clinical Cancer Research and Krankenhaus, Frankfurt

**Dr. Vicente Alonso**  
Hospital Universitario Miguel Servet, Zaragoza

**Dr. Jorge Aparicio**  
Hospital Universitari i Politècnic La Fe, Valencia

**Dr. Jaume Capdevila**  
Hospital Universitari Vall d'Hebron, Barcelona

**Dr. Andrea Cercek**  
Memorial Sloan Kettering Cancer Centre, New York

**Dr. Laura Cerezo**  
Hospital Universitario de La Princesa, Madrid

**Dr. Laura Dawson**  
Princess Margaret Cancer Centre, Toronto

**Dra. Cathy Eng**  
MD Anderson Cancer Center, Houston, Texas

**Dr. Carlos Fernández-Martos**  
Instituto Valenciano de Oncología, Valencia

**Dr. Remond Fijneman**  
The Netherlands Cancer Institute, Amsterdam

**Dr. Javier Gallego**  
Hospital Universitario, Elche

**Dr. Julio García-Aguilar**  
Memorial Sloan Kettering Cancer Centre, New York

**Dra. Rocío García-Carbonero**  
Hospital Universitario 12 de Octubre, Madrid

**Dr. Xabier García de Albéniz**  
RTI-Health Solutions, Barcelona

**Dr. Suzanne Gisbertz**  
Academisch Medisch Centrum, Amsterdam

**Dr. Robert Glynne-Jones**  
Mount Vernon Centre, Northwood

**Dr. Ajay Goel**  
Baylor institute, Dallas

**Dr. Manuel Hidalgo**  
Beth Israel Deaconess Medical Center, Boston

**Dr. Jim Kaye**  
RTI-Health Solutions, Massachusetts

**Dra. Ángela Lamarca**  
The Christie's, Manchester

**Dra. Marta Martín-Richard**  
Hospital de la Santa Creu i Sant Pau, Barcelona

**Dr. Manel Pera**  
Hospital del Mar, Barcelona

**Prof. Russell Petty**  
University of Dundee, Scotland

**Dr. Anna Reig**  
Hospital del Mar, Barcelona

**Dr. Geertjan van Tienhoven**  
Academisch Medisch Centrum, Amsterdam

Organized by:



[www.gemcad.es](http://www.gemcad.es)

Technical Secretariat:



Secretari Coloma 64-68, Esc.B, entlo. 5ª  
08024 Barcelona  
Tel. 93 43 44 412  
Fax 932 531 168  
[secretaria@gemcad.es](mailto:secretaria@gemcad.es)  
[www.mfar.es](http://www.mfar.es)

Venue:

**Hotel NH Eurobuilding**  
**Roma meeting room**  
Calle de Padre Damián, 23  
28036 Madrid

Registration fee: 363€ (taxes included)  
Access to scientific sessions

Payment: by bank transfer to GEMCAD account:  
Es70 2100 0827 12 0200707318.

To complete your registration please send your personal details (full name, hospital, service, telephone and email) to GEMCAD Technical Secretariat together with the proof of payment.

Under the auspice of:



Sponsors:

Silver



Bronze



# Updates in the multidisciplinary treatment of digestive tumors

## Madrid 4<sup>th</sup>-5<sup>th</sup> April 2019

SCIENTIFIC PROGRAM  
**Hotel NH Eurobuilding**  
**Roma meeting room**

# VII GEMCAD Symposium

Organized by:



## THURSDAY 4<sup>TH</sup> APRIL

- 16.00-18.00h** **TABLE I: Point-Counterpoint session. How to analyze and interpret randomized clinical trials: intention-to-treat vs. per-protocol analysis**  
Chair:  
Dr. Xabier García de Albéniz. RTI-Health Solutions, Barcelona
- 16.00-16.40h Pros of the intention-to-treat analysis. When and why not to use a per-protocol analysis  
Dr. Jim Kaye. RTI-Health Solutions, Massachusetts
- 16.40-17.20h Pros of the per-protocol analysis. When and why not to use an intention-to-treat analysis  
Dr. Xabier García de Albéniz. RTI-Health Solutions, Barcelona
- 17.20-18.00h Discussion
- 18.00-18.30h** **TABLE II: Radiotherapy**  
Chair:  
Dr. Laura Cerezo. Hospital Universitario de La Princesa, Madrid
- 18.00-18.20h Integration of SBRT in the treatment algorithm of gastrointestinal tumors (evidence based indications in liver metastases, pancreatic cancer and other tumors)  
Dr. Laura Dawson. Princess Margaret Cancer Centre, Toronto
- 18.20-18.30h Discussion
- 18.30-20.00h **GEMCAD GENERAL ASSEMBLY**

## FRIDAY 5<sup>TH</sup> APRIL

- 08.55-09.00h **Welcome**  
Dr. Carlos Fernández Martos. Instituto Valenciano de Oncología, Valencia
- 09.00-10.30h** **TABLE III: Esophagus and gastric cancer**  
Chairs:  
Dr. Marta Martín-Richard. Hospital de la Santa Creu i Sant Pau, Barcelona  
Dr. Manel Pera. Hospital del Mar, Barcelona
- 09.00-09.20h **Molecular subgroups in esophagus adenocarcinoma**  
Prof. Russell Petty. University of Dundee, Scotland
- 09.20-09.40h **Minimally invasive surgery for GEJ and gastric cancer**  
Dr. Suzanne Gisbertz. Academisch Medisch Centrum, Amsterdam
- 09.40-10.00h **Other criteria to take into account when a perioperative treatment is proposed**  
Dr. Salah-Eddin Al-Batran. Institute of Clinical Cancer Research and Krankenhaus, Frankfurt
- 10.00-10.30h Discussion
- 10.30-12.00h** **TABLE IV: Pancreatic and biliary ducts cancer**  
Chairs:  
Dr. Rocío García-Carbonero. Hospital Universitario 12 de Octubre, Madrid  
Dr. Anna Reig. Hospital del Mar, Barcelona
- 10.30-10.50h **New horizons for precision medicine in biliary tract cancers**  
Dr. Ángela Lamarca. The Christie's, Manchester
- 10.50-11.10h **Resectable pancreatic cancer: adjuvant and neoadjuvant strategies**  
Dr. Geertjan van Tienhoven. Academisch Medisch Centrum, Amsterdam
- 11.10-11.30h **The genomic landscape of pancreatic cancer – potential clinical implications**  
Dr. Manuel Hidalgo. Beth Israel Deaconess Medical Center, Boston
- 11.30-12.00h Discussion
- 12.00-13.00h **Lunch**

## FRIDAY 5<sup>TH</sup> APRIL

- 13.00-14.30h** **TABLE V: Colon cancer**  
Chairs:  
Dr. Vicente Alonso. Hospital Universitario Miguel Servet, Zaragoza  
Dr. Jorge Aparicio. Hospital Universitari i Politècnic La Fe, Valencia
- 13.00-13.20h **Clinical application of liquid biopsy ctDNA detection in metastatic colorectal cancer. Potential implementation in stage III**  
Dr. Remond Fijneman. The Netherlands Cancer Institute, Amsterdam
- 13.20-13.40h **New blood biomarkers in advanced metastatic colorectal cancer**  
Dr. Ajay Goel. Baylor institute, Dallas
- 13.40-14.00h **Immunotherapy in metastatic MSS colorectal cancer patients. A rational for select the best patients with optimal combination**  
Dr. Cathy Eng. MD Anderson Cancer Center, Houston, Texas
- 14.00-14.30h Discussion
- 14.30 - 16.05h** **TABLE VI: Rectal cancer**  
Chairs:  
Dr. Jaume Capdevila. Hospital Universitari Vall d'Hebron, Barcelona  
Dr. Javier Gallego. Hospital Universitario, Elche
- 14.30-14.50h **Treatment of micrometastatic disease in locally advanced rectal cancer Induction or adjuvant for c stage II and III rectal cancer**  
Dr. Andrea Cercek. Memorial Sloan Kettering Cancer Centre, New York
- 14.50-15.10h **Adjuvant Just for ypT stage III or nobody?**  
Dr. Robert Glynn-Jones. Mount Vernon Centre, Northwood
- 15.10-15.30h **Clinical complete response as a new primary endpoint in locally advanced rectal cancer**  
Dr. Julio García-Aguilar. Memorial Sloan Kettering Cancer Centre, New York
- 15.30-16.00h Discussion
- 16.00-16.05h **Conclusions and closure**